Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook compared to the market [3]. Core Insights - The report highlights the approval of the world's first invasive brain-computer interface (BCI) medical device, marking a significant milestone in clinical applications [9][35]. - The implementation of DRG/DIP 3.0 is scheduled for January 2027, which is expected to optimize payment grouping rules and enhance the efficiency of healthcare funding [38]. Market Performance - The pharmaceutical index decreased by 2.77% this week, underperforming the CSI 300 index by 0.59 percentage points, ranking 8th in industry performance [14]. - Year-to-date, the pharmaceutical index has declined by 2.9%, also trailing the CSI 300 index by 1.54 percentage points, ranking 20th [14]. Sub-industry Analysis - Among sub-industries, traditional Chinese medicine fell by 1.16%, biological products by 1.79%, chemical pharmaceuticals by 2.08%, medical devices by 4%, pharmaceutical commerce by 4.01%, and medical services by 4.32% [20]. - The medical device sector has shown the smallest decline year-to-date at -0.38%, while the chemical pharmaceutical sector has experienced the largest drop at -6.05% [20][23]. Notable Company Developments - Shanghai Ladder Medical Technology completed a strategic financing round of 500 million yuan, enhancing its clinical trial progress in the brain-computer interface sector [34]. - Eli Lilly announced a plan to invest $3 billion over the next decade to expand its supply chain in China, focusing on local production capabilities for its oral GLP-1 receptor agonist [33]. Industry News and Policies - Jiangsu Province has released an action plan for the innovative development of the brain-computer interface industry, aiming for breakthroughs in technology and the establishment of industrial clusters by 2027 [33]. - The National Medical Insurance Administration has provided updates on the DRG/DIP 3.0 version, which will enhance the payment system for hospital services [38].

Investment Rating - The report maintains a "Strong Buy" rating for Prolo Pharmaceutical (000739) [1] Core Views - The company's performance in 2025 met expectations, with revenue of 9.784 billion yuan (-18.62%) and net profit attributable to shareholders of 891 million yuan (-13.62%) [1] - The CDMO (Contract Development and Manufacturing Organization) business is expected to enter a rapid growth phase, with projected revenue growth of 16.66% in 2026 [7] - The company has a healthy project pipeline with 1,311 ongoing projects, including 398 in the commercialization phase and 913 in the R&D phase [7] Financial Summary - Total revenue for 2025 was 9,784 million yuan, with a year-on-year decline of 18.6% [3] - Net profit attributable to shareholders for 2025 was 891 million yuan, down 13.6% year-on-year [3] - The company expects a recovery in the pharmaceutical business, with projected revenues of 11.50 billion yuan in 2025, a decrease of 8.42% year-on-year [7] - The projected net profit for 2026 is 1,075 million yuan, with a growth rate of 20.6% [3] - The target price for the stock is set at 23 yuan, based on a 25x PE ratio for 2026 [7]

Market Overview - The A-share market showed an overall upward trend on March 24, with major indices mostly rising. The Shanghai Composite Index increased by 0.95%, while the Shenzhen Component Index rose by 0.26%. However, the ChiNext Index experienced a decline of 0.79% [4][3]. Sector Performance - The CXO concept sector was one of the main highlights, with a significant increase of over 3% during the morning session [8][2]. - The non-ferrous metals sector led the gains, with a rise exceeding 2.5%. Notable stocks included Rongjie Co., Haixing Co., and Guocheng Mining, which hit the daily limit [4]. - The construction materials sector also saw substantial growth, with gains over 2%. Key performers included Keshun Co., Jinjing Technology, and Dongfang Yuhong [5]. - Other sectors such as textiles and apparel, environmental protection, and public utilities also showed strong performance [6]. Notable Stocks - In the CXO sector, WuXi AppTec saw its stock price increase by over 6% in A-shares and more than 9% in Hong Kong shares [10]. - Other significant gainers included Fuxiang Pharmaceutical, which rose by 19.97%, and Meinuohua, which increased by 10.01% [9]. Company Insights - WuXi AppTec reported that as of the end of 2025, its ongoing business orders amounted to RMB 58.0 billion, reflecting a year-on-year growth of 28.8%. The company's revenue for the same period was RMB 43.42 billion, with revenue from U.S. clients reaching RMB 31.25 billion, up 34.3% year-on-year [11][12]. - The company anticipates overall revenue to reach between RMB 51.3 billion and RMB 53.0 billion in 2026, with a projected growth of 18% to 22% in ongoing business revenue [12].

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The CDMO segment has become the largest contributor to the company's gross profit, surpassing the API segment, and is expected to continue its high growth into 2026, while the API segment is anticipated to recover from its bottom [1][3] - The company reported a revenue of 9.784 billion yuan in 2025, a year-over-year decrease of 18.62%, with a net profit attributable to shareholders of 891 million yuan, down 13.62% year-over-year [2] - The CDMO business achieved a revenue of 2.198 billion yuan in 2025, reflecting a year-over-year growth of 16.66%, with a total of 1,311 ongoing projects, a 32% increase from the previous year [3] - The pharmaceutical business generated a revenue of 1.150 billion yuan in 2025, down 8.42% year-over-year, with a focus on a multi-variety development strategy [4] - The overall gross margin for 2025 was 26.36%, an increase of 2.51 percentage points year-over-year, with the CDMO segment's gross margin at 45.24%, up 4.18 percentage points [5] Financial Performance - The company generated an operating cash flow of 1.22 billion yuan in 2025, showing a year-over-year increase of 0.95%, indicating good operational quality [2] - The projected earnings per share (EPS) for 2026-2028 are expected to be 0.92, 1.09, and 1.29 yuan respectively, with a price-to-earnings (P/E) ratio of 18 times for 2026 [11]

Investment Rating - The industry investment rating is "Outperform the Market" [2][45]. Core Insights - The Shenyin Wanguo Pharmaceutical Bio Index fell by 3.21% from March 16 to March 20, 2026, ranking 10th among the first-level industries and underperforming the CSI 300 Index by 0.97 percentage points. Only the traditional Chinese medicine and biological products sectors outperformed the CSI 300 Index during this period [2][3]. - Due to geopolitical conflicts, international oil prices have been fluctuating upwards, leading to rising prices for core raw materials such as butadiene and acrylonitrile, which are essential for the disposable glove industry. This has initiated a price increase cycle in the disposable glove sector, likely boosting profits for leading companies [2][27][30]. Summary by Sections Industry Performance - The Shenyin Wanguo Pharmaceutical Bio Index's TTM price-to-earnings ratio is 47.95, which is still lower than the high valuation levels seen in 2021 [3][18]. - All sub-sectors within the pharmaceutical and biological industry experienced declines, with only traditional Chinese medicine and biological products showing relative strength against the CSI 300 Index [12][13]. Investment Recommendations - Focus on sectors with stable growth, such as medical devices and pharmaceuticals, which have stabilized competition. Recommended companies include: - Orthopedics: Sanyou Medical, Dabo Medical, Aikang Medical, Weigao Orthopedics - Ophthalmology: Aibo Medical - Cardiovascular: Huitai Medical, Xinmai Medical, Lepu Medical - In the innovative drug sector, recommended companies include: Innovent Biologics, Kintor Pharmaceutical, Kelun Pharmaceutical, Bai Li Tianheng, Betta Pharmaceuticals, Maiwei Biologics, and Nocankang [5]. - In the medical services sector, recommended companies include: Aier Eye Hospital, Tongce Medical, Haijia Medical, and Samsung Medical [5]. Key Industry News - The disposable glove industry is expected to enter a price increase cycle due to rising raw material costs, which account for a significant portion of production costs. For instance, raw materials constitute approximately 39% of the total cost for leading glove manufacturer Top Glove [30][27]. - Recent reports indicate that the prices of key raw materials like butadiene and acrylonitrile have risen significantly, with the price of acrylonitrile in the East China market increasing by 2.8% recently [29][30].

Macro and Strategy Research - The A-share market has shown a good start to the year, with a focus on reallocation opportunities as major indices adjusted recently, with the Shanghai Composite Index down 2.97% and the ChiNext Index down 0.25% [2] - Fixed asset investment in January-February increased by 1.8% year-on-year, with infrastructure investment rising significantly by 11.4%, driven by policy funding and project releases [2] - Consumer retail sales grew by 2.8% year-on-year in January-February, indicating a need for stronger consumer demand [2] Industry Research - Domestic cloud service providers have raised prices, with demand for computing power continuing to be released; for instance, Alibaba Cloud increased some product prices by up to 34% [9] - The Shanghai government plans to provide 1 billion yuan annually in computing power vouchers to establish the largest computing power scheduling platform in the country [9] - The AI computing sector is expected to see significant growth, driven by applications like OpenClaw, which have increased token usage, reflecting high demand for inference services [10] Company Research: Kelaiying (002821) - Kelaiying is a leading technology-driven CDMO service provider, focusing on small molecule CDMO and exploring emerging businesses, with a stable shareholding structure and experienced management team [6] - The company has established multiple advanced R&D centers to enhance its capabilities in small molecule drug development and production, with a steady increase in commercial projects expected from 2023 to 2024 [6] - Emerging business areas are being actively developed, leveraging the company's extensive experience in the pharmaceutical industry to create a one-stop custom service platform for innovative drugs [7] Company Research: Small Molecule CDMO - The small molecule CDMO sector is experiencing steady growth, with the company enhancing its capabilities in peptide and oligonucleotide CDMO, driven by market demand [7] - The company is focusing on ADC and has a robust order book, with international service capabilities continuously improving [7] - Clinical CRO business is also seeing a return to growth, with new projects being undertaken in various disease areas [7] Company Valuation - Under a neutral scenario, the company is expected to have EPS of 3.15, 3.65, and 4.28 yuan per share for 2025-2027, with a PE ratio of 27.27 for 2026, and an "overweight" rating is given [8]

Investment Rating - The report maintains an "Overweight" rating for the biopharmaceutical and chemical pharmaceutical sectors [6]. Core Insights - The Chinese innovative drug sector is at the beginning of a long cycle, with continuous global output of high-quality assets from Chinese companies. The potential of these assets is not fully reflected in A/H share pricing, leading to a recommendation for the innovative drug sector [1]. - The number and value of business development (BD) deals in the Chinese innovative drug industry have reached record highs in 2023, with 45 BD deals completed (+73% year-on-year) and a total disclosed amount of $57.5 billion (+135% year-on-year) [2]. - The report highlights a significant valuation gap between A/H shares and US stocks for similar innovative drug assets, indicating that A/H shares are systematically undervalued [4]. Summary by Sections Business Development Trends - The report notes that the Chinese innovative drug sector has achieved a global market share of approximately 20% in the number of BD projects and around 75% in the disclosed amount [2]. - There is a high predictability of continued growth in BD activities, driven by increasing interest from multinational corporations (MNCs) and private equity (PE) firms in Chinese assets [2]. Cash Flow Contributions - The report emphasizes that platform companies in China are expected to generate sustainable cash flows through ongoing BD activities, which have not been adequately valued in the market [3]. - It is projected that significant BD deals (with upfront payments exceeding $500 million) will contribute to continuous cash flow growth for companies like Heng Rui Medicine, Shiyao Group, and others [3]. Valuation Comparisons - The report compares the valuations of similar assets in A/H shares and US markets, revealing that Chinese innovative drug companies are undervalued relative to their US counterparts [4][19]. - Specific case studies illustrate the valuation discrepancies, such as between MSD and Kelun Biotech, and Insmed and Haizhi Pharmaceutical, highlighting the potential for significant upside in A/H share valuations [19][22]. Investment Recommendations - The report recommends focusing on large pharmaceutical and biopharmaceutical companies with sustained BD capabilities, including Heng Rui Medicine, Shiyao Group, and others [5]. - Companies that have completed large BD deals are expected to benefit from ongoing milestone cash flows, with specific recommendations for companies like Kelun Biotech and Rongchang Biopharmaceutical [5]. Target Prices and Market Outlook - Target prices for recommended stocks are provided, with specific price targets for companies such as Shiyao Group at HKD 19.25 and Heng Rui Medicine at HKD 98.43, indicating a bullish outlook for these stocks [26].

Investment Rating - The report maintains a "Buy" rating for the company, highlighting the stability of its main business and the uniqueness of its molecular glue platform [5][7]. Core Insights - The company has shown a robust revenue growth from CNY 162 million in 2013 to CNY 1.35 billion in 2024, with a compound annual growth rate (CAGR) of 21.3%. The market share of its anesthetic analgesic products continues to rise [6][9]. - The company is advancing from a model of "high-end generics + modified drugs" to "innovative anesthesia + molecular glue + small molecule innovative drugs," which is expected to significantly enhance its long-term growth trajectory [6][9]. - The core product HP-001, a CRBN molecular glue, demonstrates best-in-class potential and is positioned to capture a significant market share in the treatment of relapsed/refractory multiple myeloma and non-Hodgkin lymphoma [6][9]. Financial Performance and Forecast - The company forecasts revenues of CNY 1,332 million in 2025, with a year-on-year growth rate of -1.33%, followed by CNY 1,513 million in 2026 and CNY 1,728 million in 2027, with growth rates of 13.63% and 14.16% respectively [5][7]. - The projected net profit attributable to shareholders is CNY 283 million in 2025, CNY 313 million in 2026, and CNY 358 million in 2027, with corresponding growth rates of 18.79%, 10.63%, and 14.51% [5][7]. - The price-to-earnings (P/E) ratios are expected to be 38.69, 34.97, and 30.54 for the years 2025, 2026, and 2027 respectively [5][7]. Business Strategy and Product Pipeline - The company has a diverse product matrix in anesthetic analgesics, with 18 marketed products and over 20 in clinical development. The internationalization of its products is expected to contribute to revenue growth [6][9]. - The company is focusing on innovative drug development through its subsidiary, Chaoyang Pharmaceutical, which specializes in molecular glue and other cutting-edge technologies [6][9]. - The company is also advancing several small molecule candidates and has a robust pipeline that includes EP-9001A, EP-0226, and EP-0210, which are in various stages of clinical trials [6][9]. Market Position and Competitive Landscape - The company is positioned well within the market, with a significant share in the anesthetic analgesic sector, and is actively expanding its international presence [6][9]. - The report compares the company with peers such as Haikang Pharmaceutical, Puluo Pharmaceutical, Enhua Pharmaceutical, and Aosaikang, indicating a favorable competitive landscape for the company's growth strategy [5][7].

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the **biomedical industry** in China, highlighting its elevation as a new pillar industry in the national development plan, particularly focusing on **biomanufacturing, brain-computer interfaces, high-end medical devices, and innovative drug development** [1][2]. Core Insights and Arguments - **Policy Direction**: The top-level design of the biomedical industry policy emphasizes two core directions: "strong innovation" and "benefiting people's livelihood." The industry is recognized for its economic importance and social function, with a focus on improving the healthcare system [2][3]. - **Medicare Adjustments**: In 2026, the per capita financial subsidy for Medicare is planned to increase by **24 yuan**, a slight decrease from the **30 yuan** increase in 2025, indicating a continued trend of increasing government subsidies despite a slight adjustment in growth rate [2]. - **Support for Innovative Drugs**: The 2025 Medicare drug list adjustment reflects strong support for "true innovation," with **40%** of the newly added **114 drugs** being first-class new drugs, and **50%** of these being biological products [5][6]. - **Renewal Rules**: The renewal rules for drugs in the Medicare directory show a stable support attitude towards high-value mature products, with **92%** of drugs renewing without price reductions [6]. - **Commercial Insurance Directory**: The first commercial insurance directory introduced in 2025 included **19 out of 141** reported drugs, focusing on high-innovation products and offering significant policy benefits [7][8]. - **Accelerating Domestic Drug Access**: Measures have been taken to accelerate the access of domestic innovative drugs to hospitals, including a requirement for medical institutions to hold drug committee meetings within **three months** of the Medicare directory release [9]. Additional Important Content - **Consolidation in Retail Pharmacy**: The retail pharmacy industry is expected to enter a phase of high-quality development and horizontal mergers starting in 2026, with policies encouraging pharmacies to execute equal outpatient insurance treatment as grassroots medical institutions [11]. - **IVD Sector Developments**: The IVD sector is seeing significant changes, including a focus on reducing the number of chargeable items and ensuring that AI-assisted diagnostics do not incur additional fees [17][18]. - **Medical Device Industry Trends**: The medical device industry is experiencing a slowdown in bidding procurement growth, with an expansion of centralized procurement covering about **30%** of the industry, particularly in county-level medical communities [19][20]. - **Medicare Payment Reform**: The upcoming **DRG/DIP 3.0** version is expected to provide more specific support for innovation, while a nationwide pilot for traditional Chinese medicine payment by disease will also be initiated [20][21]. - **Regulatory Changes**: New regulatory measures are being implemented to enhance the efficiency of Medicare fund clearing and to apply AI technology in regulatory processes [22]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future direction of the biomedical industry in China.

1. Report Industry Investment Rating - No relevant information provided 2. Core View of the Report - On March 16, the capital market remained loose; inflation expectations intensified, causing the bond market to weaken under pressure; the main indices of the convertible bond market closed down collectively, and most convertible bond issues declined; the yields of U.S. Treasuries across all maturities generally decreased, and the yields of 10-year government bonds in major European economies generally decreased [1] 3. Summary by Relevant Catalogs 3.1 Bond Market News 3.1.1 Domestic News - From March 15 - 16, China and the U.S. held economic and trade consultations in Paris, France, and reached some new consensuses [3] - On March 16, Premier Li Qiang chaired the 11th plenary meeting of the State Council, deploying the implementation of key tasks in 2026 [4] - Data from January - February showed that major economic indicators significantly rebounded, with industrial added value, fixed - asset investment, and social consumption rising [5] - In February, the bank settlement and sales of foreign exchange surplus reached $42.8 billion, a 46% decline from the previous month [6] - The Ministry of Natural Resources and the National Forestry and Grassland Administration introduced a notice linking new construction land with the revitalization of existing land [7] - The Financial Regulatory Administration launched a regulatory rating for wealth management companies [8] 3.1.2 International News - On March 16, manufacturing activity in New York State stagnated, but inflation expectations eased [9] 3.1.3 Commodities - On March 16, international crude oil futures prices turned down, and MYMEX natural gas futures prices continued to fall [10] 3.2 Capital Market 3.2.1 Open Market Operations - On March 16, the central bank conducted 7 - day reverse repurchase operations of 137.3 billion yuan, resulting in a net capital injection of 88.8 billion yuan [12] 3.2.2 Capital Interest Rates - On March 16, the capital market remained loose, with DR001 rising 0.01bp to 1.322% and DR007 falling 0.93bp to 1.452% [13] 3.3 Bond Market Dynamics 3.3.1 Interest Rate Bonds - On March 16, due to high international oil prices, inflation expectations intensified, and the bond market weakened. The yields of 10 - year Treasury bonds and 10 - year China Development Bank bonds increased [15] - Multiple bonds were issued on March 16, with details such as issue scale and winning bid yields provided [17] 3.3.2 Credit Bonds - On March 16, the trading price of "H3 Vanke 01" deviated by over 10%, falling more than 13% [17] - Multiple credit bond events occurred, including debt restructuring, non - full repayment of debt funds, asset transfers, and rating adjustments [18] 3.3.3 Convertible Bonds - On March 16, the A - share market had mixed performance, and the main indices of the convertible bond market closed down. Most convertible bond issues declined [18][19] - Some convertible bonds were about to be subscribed online, and some announced changes in conversion prices [24] 3.3.4 Overseas Bond Markets - On March 16, the yields of U.S. Treasuries across all maturities generally decreased, and the yield spreads between some maturities changed [22][25] - The yields of 10 - year government bonds in major European economies generally decreased [27] - The daily price changes of Chinese - funded U.S. dollar bonds as of the close of March 16 were provided [29]